Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L. Alves, Henrik J. Ditzel|Nature Communications|2021Cited by 82
Functional Heterogeneity within the CD44 High Human Breast Cancer Stem Cell-Like Compartment Reveals a Gene Signature Predictive of Distant MetastasisRikke Leth‐Larsen, Henrik J. Ditzel|Molecular Medicine|2012Cited by 79
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancerAbeer J. Al-Qasem, Henrik J. Ditzel|npj Precision Oncology|2022Cited by 72
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cellsMikkel G. Terp, Henrik J. Ditzel|npj Precision Oncology|2021Cited by 46
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasisOdd Lilleng Gammelgaard, Henrik J. Ditzel|Molecular Cancer|2024Cited by 14